Live News EQUITY ARTICLE M impact Aug 19, 2026, 10:45 AM UTC

Merck, Moderna report positive phase 3 melanoma results

Merck and Moderna say the phase 3 INTERPATH-001 trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected Stage IIb-IV melanoma.

MRNA MRK

SquawkNews Newsroom 1 updates Updated Aug 19, 2026, 10:47 AM UTC

Story updates

10:47:58 AM UTC

SquawkNews

Merck $MRK and Moderna $MRNA personalized mRNA cancer vaccine slowed the return of melanoma and its spread to other parts of the body in a Ph3 clinical trial. No data disclosed yet, but the study was stopped for positive results at the first interim analysis. Magnitude of benefit TBD, but this is a potentially huge breakthrough for cancer patients and the use of mRNA to treat cancer. Adam F X post

MRK MRNA (more) Merck: Co, Moderna announce positive results from phase 3 interpath-001 trial for patients with completely resected Stage iib-iv melanoma Merck: phase 3 interpath-001 trial of intismeran autogene plus Keytruda met primary endpoint of recurrence free survival - Phase 3 interpath-001 trial of intismeran autogene plus Keytruda met a key secondary endpoint of distant metastasis-free survival - Safety profiles of intismeran and Keytruda in trial were consistent with prior reported studies for the combination - Co, Moderna will engage with regulators on filing submissions for intismeran autogene in combination with Keytruda